Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 10/13/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Michael Haude

Wrong Dr. Michael Haude?

Chief of Cardiology

Local Address:  Neuss , Germany

Employment History

  • Director of Medical Clinic I
  • Professor of Internal Medicine
  • Chief of Cardiology
    Stadtische Kliniken Neuss
  • Professor

Board Memberships and Affiliations

  • Board Member
  • Board Member
    Medizinische Klinik I


  • M.D.
  • MD
48 Total References
Web References
"The results of BIOSOLVE-II confirm that ..., 13 Oct 2015 [cached]
"The results of BIOSOLVE-II confirm that the BIOTRONIK Magnesium Scaffold is both a safe and effective option for treating coronary artery disease (CAD), and establish it as the first clinically-proven magnesium-based bioresorbable scaffold," commented principal investigator of the study Dr. Michael Haude of the Lukaskrankenhaus, Neuss, Germany.
It is based on a natural element widely present in the human body, and the magnesium-based properties promote a faster and simpler implantation procedure," commented Dr. Haude.
This analysis takes the next step ..., 9 Sept 2015 [cached]
This analysis takes the next step in projecting that these benefits result in the cost effectiveness of the therapy," said Michael Haude, M.D. PhD, Chief of Cardiology at Lukaskrankenhaus in Neuss, Germany and co-author of the study.
"Late stent thrombosis is still a ..., 27 May 2013 [cached]
"Late stent thrombosis is still a concern for patients treated with monotherapy DES, leaving them dependent on a minimum of six months DAPT," said Michael Haude , M.D., director of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, and principal investigator of the REMEDEE trial.
The dual therapy stent was shown ..., 29 Nov 2011 [cached]
The dual therapy stent was shown to be safe and effective, as well as non-inferior to the paclitaxel-eluting stent, according to lead researcher Michael Haude, Professor of Internal Medicine at Lukaskrankenhaus Neuss in Germany. Results of the REMEDEE trial were presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Visit Cardiology page. - Board Members, 14 July 2015 [cached]
Michael Haude
Other People with the name "Haude":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.